Technical Analysis for ZLDPF - Zealand Pharma A/S Ord

Grade Last Price % Change Price Change
grade A 21.6 -1.19% -0.2600
ZLDPF closed down 1.19 percent on Friday, August 16, 2019, on 3 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Up
See historical ZLDPF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -1.19%
Outside Day Range Expansion -1.19%
Wide Bands Range Expansion -1.19%
Overbought Stochastic Strength -1.19%
Stochastic Sell Signal Bearish -1.93%

Older signals for ZLDPF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Biotechnology RTT Medical Specialties Diabetes Organ Systems Endocrine System Eli Lilly And Company Peptide Hormones Sanofi Recombinant Proteins Short Bowel Syndrome Treatment Of Short Bowel Syndrome Congenital Hyperinsulinism Lixisenatide
Is ZLDPF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 22.6
52 Week Low 12.1001
Average Volume 6,066
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 17.5158
10-Day Moving Average 19.6145
Average True Range 1.1759
ADX 20.92
+DI 58.8536
-DI 36.6894
Chandelier Exit (Long, 3 ATRs ) 19.0723
Chandelier Exit (Short, 3 ATRs ) 15.6278
Upper Bollinger Band 24.3289
Lower Bollinger Band 10.7027
Percent B (%b) 0.8
BandWidth 77.793763
MACD Line 2.764
MACD Signal Line 1.891
MACD Histogram 0.873
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.6450
Resistance 3 (R3) 21.6500 21.6400 21.6375
Resistance 2 (R2) 21.6400 21.6285 21.6375 21.6350
Resistance 1 (R1) 21.6200 21.6215 21.6150 21.6150 21.6325
Pivot Point 21.6100 21.6100 21.6075 21.6075 21.6100
Support 1 (S1) 21.5900 21.5985 21.5850 21.5850 21.5675
Support 2 (S2) 21.5800 21.5915 21.5775 21.5650
Support 3 (S3) 21.5600 21.5800 21.5625
Support 4 (S4) 21.5550